BIOTECH SQUIRE
Methodology & Architecture

How We Build Your Partnering Environment.

A structured four-part engineering sequence designed to transform scattered executive threads into a clean, auditable partnering pipeline without burdening scientific operations.

01 Mapping Active Pharma Context

Workflow & Thread Audit

We begin by mapping active pharma conversations, follow-ups from major partnering conferences (BIO International Convention, BIO-Europe, J.P. Morgan Healthcare Week) and online partnering portals (partneringONE, BIO One-on-One Partnering), and the specific reporting requirements of your leadership team, Board of Directors, or prospective Series A syndicate.

Architectural Output
  • Review asset-level partnering tracks and active counterparties
  • Catalog conference and portal follow-ups alongside historical diligence threads
  • Align pipeline structure with upcoming board and financing milestones
02 Biopharma Stages & Privacy Governance

Custom Pipeline Architecture

We configure dedicated biopharma deal stages, deterministic court ownership labels, and structured pass/pause taxonomies—paired with two-way Outlook/Gmail sync equipped with a 1-click privacy lock to keep personal or sensitive threads excluded from shared deal records.

Architectural Output
  • Stages: Non-Confidential Outreach, CDA Executed, Data Room & Scientific Diligence, Term Sheet / Negotiation
  • Status ownership: Active — Ball in Our Court vs. Active — Ball in Pharma's Court
  • Taxonomy: Conditional Pass — Future Data Trigger vs. Hard Pass with structured rationale
03 Noise Filtering & Telemetry Hygiene

Human-Verified Historical Migration

Rather than running automated bulk inbox imports that pollute deal records, we manually structure prior pharma discussions while filtering out CRO, legal, vendor, and administrative noise—ensuring only accurate partnering telemetry enters the system.

Architectural Output
  • Manual separation of genuine pharma BD threads from operational vendor mail
  • Preservation of prior feedback tied to upcoming preclinical or clinical readouts
  • Clean contact and organizational mapping across search-and-evaluation counterparts
04 Effortless Team-Wide Adoption & Board Readiness

Team Enablement & Reporting Views

We equip executive leadership and scientific contributors with streamlined inbox logging workflows and configure clean reporting views tailored for recurring board packets and Series A data rooms.

Architectural Output
  • Minimal-friction email and meeting capture directly from existing inboxes
  • Consistent board-ready visibility across active and paused pharma conversations
  • Clear inactivity visibility so high-value external innovation threads stay moving
Operating Scope & Boundaries

Clear Division Between Operational Infrastructure and Scientific Judgment.

What Biotech Squire Engineers
  • Partnering pipeline governance structured around biopharma diligence stages
  • Human-verified historical migration separating pharma BD context from vendor noise
  • Privacy-locked inbox sync and clean reporting views for Boards and Series A diligence
What Stays With Leadership
  • Scientific, preclinical, clinical, and intellectual property strategy or evaluation
  • Regulatory positioning across FDA Pre-IND & EMA Scientific Advice interactions
  • Direct pharma relationship building and business development outreach (never outsourced)
Discretion by Design

Confidentiality, Security & CDA Governance

Mutual CDAs as Standard Practice

Biotech Squire routinely operates under mutual Confidential Disclosure Agreements (CDAs) before any partnering records are handled.

Strict Workspace Access Isolation

Each client operates in an isolated workspace. Access is limited to named leadership and team members you authorize.

No Model Training on Client Data

Client data is never shared with third parties and is never used to train external models.

Institutional-Grade Discretion

Sensitive asset details and counterparty discussions are handled with the discretion expected in pre-IND and early clinical partnering.

Discuss Your Current Partnering Workflow.

Book a 15-minute introductory call to assess fit for your asset stage and governance roadmap.

Book a Call